Home > Search Clinical Trials > Cardiovascular (Heart, High Blood Pressure, Etc.)

IRB No. 02-200-1 (Dr. Bruce Liang, PI): Molecular Correlates of Atrial Fibrillation

Study description not available

IRB No. 06-151-2 (Dr. Bruce Liang, PI): Circulating markers that underlie the transition from compensated hypertrophy to heart failure

Early detection and prevention are key features in treating subjects with heart failure. We are looking to see of caspase-3 and dystrophin can be detected in human circulation. If so, we will determine whether they are predictors for the transition between compensated and de-compensated heart failure.

IRB No. 07-252-2: Circulating Markers for Ischemic Heart Failure

The purpose of this research is to determine if two proteins in the blood are increased during acute myocardial infarction and whether their levels are higher in those who develop heart failure than those who do not. These two proteins are produced and potentially released when the heart muscle is damaged. They may then be released into the blood and be detected by standard method in the research laboratory. At this time, detection of an increase in these proteins in the blood is not know to be associated with any disease or myocardial infarction.

IRB No. 18-170-1 (Dr. Sara Tabtabai, PI): Evaluation of a Guideline Directed Medication Titration (GDMT) Program in Patients with Heart Failure with Reduced Ejection Fraction

A patient newly diagnosed with heart failure with reduced ejection fraction requires close follow up for titration of medications as blood pressure, electrolytes and symptoms permit. Although the benefits of guideline directed medical therapy (GDMT) have been well studied, there remains a significant gap in the receipt of GDMT in the ambulatory and hospitalized setting. As such, we seek to assess the utility of focused GDMT clinic to reduce this gap. We hypothesize that implementation of a GDMT focused clinic will reduce the gap, improve medication compliance and in turn, improve the mean ejection fraction, and reduce hospitalization rates.

IRB No. 18-228-2: Assessment of Myocardial Deformation in Adult Patients with Type 2 Diabetes Mellitus

This retrospective case-control study aims to determine if patients with early-stage diabetic cardiomyopathy have subtle myocardial deformation usingspeckletracking echocardiogram. The two aims of the study are (1)to determine whether adult diabetic patients with preserved left ventricular ejection fraction have abnormalities in myocardial deformation and (2) to determine whether adult diabetic patients have impaired diastolic function as assessed by traditional methods as well as by novel method, i.e. left atrial strain, a measurement that has been shown to correlate with pulmonary capillary wedge pressure.

IRB No. 22-145-2 (Dr. Christopher Pickett, PI): Effect of Beta-blocker Discontinuation on Functional Capacity and Cardiac Hemodynamics in Patients with Heart Failure with Preserved Ejection Fraction

Heart failure (HF) is a growing public health problem associated with significant mortality and healthcare cost. Heart failure (HF) can be classified into two distinct types based on cardiac muscle contractility measured as ejection fraction - HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). Significant advances in the HF therapy over the past decades have substantially improved the outcome in patients with HFrEF. In contrast, there is no effective therapy available for HFpEF, which remains to be the ";single largest unmet need in cardiovascular medicine";1. Beta-blocker (BB) - The survival benefit of BB in treating HFrEF 3, but not HFpEF, has been well established. Despite of lacking evidence, BB use was shown in 80% of HFpEF patients enrolled in both TOPCAT and PARAGON-HF trials4,5, and in 66% of HFpEF patients in our observational study excluding atrial fibrillation and CAD. This pilot study is to evaluate the effect of beta-blocker withdrawal on functional capacity and cardiac hemodynamics in patients with HFpEF.